Streetbeat News

Analyst Ratings

SHW

Sherwin-Williams (NYSE:SHW) has received various analyst ratings in the last quarter, with 5 bullish, 2 somewhat bullish, and 5 indifferent. The average price target is $268.5, compared to its current price of $259.835, implying an upside. The average price target has increased by 7.21% over the past month.

Portfolio Pulse from Benzinga Insights

July 05, 2023 | 7:01 pm

VICI

VICI Props (NYSE:VICI) has received three somewhat bullish ratings, one indifferent rating, and no bearish ratings from analysts in the last quarter. The average 12-month price target for the stock is $37.75, representing a 1.95% decrease from the previous average price target of $38.50.

Portfolio Pulse from Benzinga Insights

July 05, 2023 | 7:00 pm

NDLS

Analysts have provided various ratings for Noodles (NASDAQ:NDLS) within the last quarter, with 2 bullish, 1 somewhat bullish, and 1 indifferent. The average 12-month price target for Noodles is $6.5, representing an 18.75% decrease from the previous average price target of $8.00.

Portfolio Pulse from Benzinga Insights

July 05, 2023 | 7:00 pm

AXTA

In the last quarter, Axalta Coating Sys (NYSE:AXTA) received 3 bullish, 1 somewhat bullish, 2 indifferent, and 1 somewhat bearish ratings from analysts. The average price target is $33.86, indicating an upside from the current price of $32.165. This average has increased by 12.87% from the previous target of $30.00.

Portfolio Pulse from Benzinga Insights

July 05, 2023 | 7:00 pm

GBX

KeyBanc Capital Markets analyst Steve Barger reiterated the Sector Weight rating on Greenbrier Companies (NYSE:GBX), following a strong 3Q report and a solid preliminary 4Q order book. Barger expects more orders for GBX as the quarter progresses, reversing the trend of backlog declines. The analyst is also optimistic about easing supply chain constraints and cost-saving initiatives contributing to margin expansion. Barger raised EPS estimates for FY23, FY24, and FY25, and remains optimistic about GBX's progress towards its cost optimization goal.

Portfolio Pulse from Nabaparna Bhattacharya

July 05, 2023 | 6:59 pm

DXCM

DexCom Inc.'s stock has increased by 6.75% over the past month and by 55.82% over the past year. The company's P/E ratio of 178.9 is higher than the Health Care Equipment & Supplies industry average of 153.77, suggesting that the stock might be overvalued. However, the P/E ratio should not be used in isolation for investment decisions, as other factors such as industry trends and business cycles can also impact a company's stock price.

Portfolio Pulse from Benzinga Insights

July 05, 2023 | 6:51 pm

NPO

KeyBanc Capital Markets analyst Jeffrey D. Hammond has reiterated an Overweight rating on EnPro Industries Inc (NYSE:NPO), raising the price target to $158 from $145. Hammond is optimistic about the company's core businesses within the Sealing Technologies segment. He expects 2Q revenues of $171.4 million in this segment. Hammond also notes that EnPro is beginning to see synergies between Leanteq and NxEdge, and considers the company a key beneficiary of CHIPS Act investment. He believes NPO shares are undervalued at current levels and expects valuation multiples to re-rate higher in the long term.

Portfolio Pulse from Nabaparna Bhattacharya

July 05, 2023 | 6:50 pm

NXT

Truist Financial analyst Jordan Levy maintained a Buy rating on NEXTracker, Inc (NASDAQ:NXT) despite the company's recent share price discount. NEXTracker announced the pricing of a follow-on offering of ~18.2 million shares at $36.50 per share, a ~6% discount to the stock's closing price on June 23. Levy remains bullish on NXT's U.S. and international growth prospects amidst accelerating utility-scale solar development. NXT shares traded lower by 1.93% at $38.67 on the last check Wednesday.

Portfolio Pulse from Anusuya Lahiri

July 05, 2023 | 6:47 pm

BTCY

H.C. Wainwright analyst Kevin Dede reiterated a Buy rating on Biotricity, Inc. (NASDAQ:BTCY), raising the price target to $4 from $2. The analyst acknowledged Biotricity's sales and targeted margin growth, AI tech infusion, and the opportunity to bring its platform solution to associated cardiac-related diseases. For FY24, the analyst's sales estimate stands at $13.8 million, representing an expected 44% annual growth. However, an investment in Biotricity is subject to risks like dilution, end-market product acceptance and pricing, and competition.

Portfolio Pulse from Nabaparna Bhattacharya

July 05, 2023 | 6:41 pm

BKNG

A significant bearish stance has been taken on Booking Holdings (NASDAQ:BKNG) by a large investor or institution, as indicated by unusual options activity. The sentiment among these big-money traders is 5% bullish and 94% bearish. Whales have been targeting a price range from $2300.0 to $3500.0 for Booking Holdings over the last 3 months. The price of BKNG is currently down -1.54% at $2678.81. Wedbush and Wells Fargo have downgraded their actions on BKNG with price targets of $3060 and $2257 respectively.

Portfolio Pulse from Benzinga Insights

July 05, 2023 | 6:31 pm